Pyrazoline Derivatives as CB1 Receptor Agonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CB1 receptor modulators lack compounds with agonistic activity, and there is a need for novel compounds that can effectively target cannabinoid receptors for therapeutic applications in various disorders.
Innovation Solution
Development of 4,5-dihydro-(1H)-pyrazole derivatives with modified 3-aryl or 3-heteroaryl groups and substitution patterns at the 1-position, which exhibit potent CB1 receptor affinity, acting as agonists, partial agonists, antagonists, or inverse agonists, and also show affinity for CB2 receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing pyrazoline derivatives are used, then vermin controlling activity is achieved, but CB1 receptor agonistic activity is not obtained
Solution Approach 1:
The patent applies local quality by introducing specific substituents at defined positions on the pyrazoline core structure. Different substituents (R1-R6) are placed at specific locations to create distinct pharmacological profiles, allowing some compounds to act as agonists while others act as antagonists or inverse agonists at CB1 receptors.
Solution Approach 2:
The patent systematically varies chemical parameters including substituent types, positions, and configurations on the pyrazoline scaffold. By changing these molecular parameters, the invention transforms compounds from vermin controllers to CB1 receptor modulators with agonistic, antagonistic, or inverse agonistic activities suitable for human therapeutic applications.
2Adaptability or versatility
If novel pyrazoline structures with CB1 affinity are developed, then therapeutic applications are expanded, but compound complexity increases
Solution Approach 1:
The patent segments the molecular design into a core pyrazoline structure with distinct substitutable positions (R1-R6). This modular approach allows systematic exploration of structure-activity relationships while maintaining a manageable core framework, balancing complexity with therapeutic versatility.
Solution Approach 2:
The pyrazoline scaffold serves as a universal platform that can generate multiple pharmacological activities (agonist, antagonist, inverse agonist) through substituent variation. This multi-functional design allows a single core structure to address multiple therapeutic indications including psychosis, anxiety, depression, and neurological disorders.
Data Source
AI summary
This invention is directed to 4,5-dihydro -(1 H)-pyrazole (pyrazoline) derivatives as cannabinoid CB1 receptor modulators, to pharmaceutical compositions containing these compounds, to methods for the preparation of these compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in disorders in which CB1 receptors are involved, or that can be treated via manipulation of those receptors. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.